Free Trial
NASDAQ:ONVO

Organovo (ONVO) Stock Price, News & Analysis

Organovo logo

About Organovo Stock (NASDAQ:ONVO)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$1.66
$15.24
52-Week Range
N/A
Volume
243,634 shs
Average Volume
617,505 shs
Market Capitalization
$3.47 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive 3D bioprinted human liver tissue with distinct hepatocellular and non-parenchymal cell compartments. The company was incorporated in 2007 and is headquartered in San Diego, California.

Receive ONVO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Organovo and its competitors with MarketBeat's FREE daily newsletter.

ONVO Stock News Headlines

Two new option listings and one option delisting on April 24th
Trump wipes out trillions overnight…
Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out nearly $5 trillion in wealth from the S&P 500 and $6.4 trillion from the Dow Jones… Not to mention the countless trillions of dollars lost in every market around the world… leaving the major political powers scrambling in fear of Trump’s next move.
VivoSim to Carry Forward Organovo 3D Bioprinting
See More Headlines

ONVO Stock Analysis - Frequently Asked Questions

Organovo Holdings, Inc. (NASDAQ:ONVO) released its quarterly earnings data on Wednesday, February, 19th. The medical research company reported ($2.28) EPS for the quarter, beating the consensus estimate of ($2.52) by $0.24. The medical research company had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.05 million. Organovo had a negative trailing twelve-month return on equity of 346.26% and a negative net margin of 10,151.64%.

Organovo shares reverse split on Friday, March 21st 2025. The 1-12 reverse split was announced on Wednesday, March 19th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, March 20th 2025. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

Shares of ONVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Organovo investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), NIO (NIO), Brainstorm Cell Therapeutics (BCLI), AST SpaceMobile (ASTS) and Virgin Galactic (SPCE).

Company Calendar

Last Earnings
2/19/2025
Today
6/07/2025
Fiscal Year End
3/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ONVO
Fax
N/A
Employees
20
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$14.67 million
Net Margins
-10,151.64%
Pretax Margin
-10,150.00%

Debt

Sales & Book Value

Annual Sales
$122 thousand
Price / Cash Flow
N/A
Book Value
$0.02 per share
Price / Book
N/A

Miscellaneous

Free Float
14,794,000
Market Cap
$3.47 million
Optionable
Optionable
Beta
1.13

Social Links

The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:ONVO) was last updated on 6/7/2025 by MarketBeat.com Staff
From Our Partners